A phase II trial of 2,5,-diaziridinyl 3,6-bis (carboethoxy amino) 1,4-benzoquinone (AZQ, NSC 182986) in recurrent primary brain tumors

Lynn G. Feun, Wai Kwan A. Yung, Milam E. Leavens, M. Andrews Burgess, Eugenie A. Obbens, Agop Y. Bedikian, Niramol Savaraj, David J. Stewart, Robert S. Benjamin, William S. Fields, G. P. Bodey

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

Forty-one patients with recurrent primary malignant brain tumors were treated with 2,5-diaziridinyl 3,6-bis (carboethoxyamino), 1,4-benzoquinone (AZQ) at an initial dose of 6-8 mg/m2/ day × 5 days. Courses were repeated monthly upon recovery of myelosuppression. Six of 25 evaluable patients (24%) showed definite tumor regression, and 7 (28%) showed disease stability as determined by monthly CT scans and neurologic examination. For all patients receiving one course of AZQ, the response rate was 16% (6 of 37 patients) and the stable disease rate 19%. The estimated median time to tumor progression with AZQ was 54 weeks for the responding patients and 36 weeks for the stable patients. Toxicity consisted of myelosuppression, primarily thrombocytopenia, which was delayed and cumulative. Other toxicities were uncommon. Further clinical trials in patients with malignant primary brain tumors, including combination studies with other drugs, are indicated.

Original languageEnglish (US)
Pages (from-to)13-17
Number of pages5
JournalJournal of neuro-oncology
Volume2
Issue number1
DOIs
StatePublished - Mar 1 1984
Externally publishedYes

Keywords

  • AZQ
  • brain tumor

ASJC Scopus subject areas

  • Neuroscience(all)
  • Oncology
  • Clinical Neurology
  • Cancer Research

Fingerprint Dive into the research topics of 'A phase II trial of 2,5,-diaziridinyl 3,6-bis (carboethoxy amino) 1,4-benzoquinone (AZQ, NSC 182986) in recurrent primary brain tumors'. Together they form a unique fingerprint.

Cite this